Latest news with #EmbectaCorp
Yahoo
24-07-2025
- Business
- Yahoo
embecta to Report Fiscal Third Quarter 2025 Financial Results
PARSIPPANY, N.J., July 24, 2025 (GLOBE NEWSWIRE) -- Embecta Corp. ('embecta') (Nasdaq: EMBC), a global company that is advancing its 100-year legacy in insulin delivery to become a broad-based medical supplies company, will host a conference call to discuss its fiscal third quarter 2025 financial results, provide an operational update, and host a question and answer session, at 8:00 a.m. Eastern Time (ET) on Friday, August 8, 2025. Those who would like to participate may access the live webcast here, or access the teleconference here. The live webcast can also be accessed via the company's website at A webcast replay of the call will be available beginning at 11:00 a.m. ET on August 8, 2025, via the embecta investor relations website and archived on the website for one year. About embecta embecta is a global company that is advancing its 100-year legacy in insulin delivery to become a broad-based medical supplies company, helping to improve lives through innovative solutions, partnerships, and the passion of approximately 2,000 employees around the globe. For more information, visit or follow our social channels on LinkedIn, Facebook, and Instagram. Contacts: Media Investors Christian Glazar Pravesh Khandelwal Sr. Director, Corporate Communications VP, Head of Investor Relations 908-821-6922 551-264-6547 Contact Media Relations Contact IRError in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
13-07-2025
- Business
- Yahoo
BTIG Lowers PT on Embecta Corp. (EMBC) to $25, Keeps a Buy Rating
Embecta Corp. (NASDAQ:EMBC) is one of the best cheap stocks with huge upside potential. On May 23, BTIG analyst Marie Thibault lowered the firm's price target on Embecta Corp. (NASDAQ:EMBC) to $25 from $26, keeping a Buy rating on the shares. The rating followed its Investor Day presentation. An assembly line of medical devices being packed for distribution. The analyst told investors in a research note that Embecta Corp. (NASDAQ:EMBC) reaffirmed its FY2025 guidance, with long-range targets offered through fiscal year 2028. In addition, Embecta Corp.'s (NASDAQ:EMBC) lower margin outlook compared to fiscal year 2025 reflects pricing pressure, inflationary headwinds, and incremental tariffs. The firm added that these factors are partially offset by cost improvement programs. Embecta Corp. (NASDAQ:EMBC) provides medical devices used to treat diabetes. The company's offerings include syringes, pen needles, and safety devices fitted with a digital application. While we acknowledge the potential of EMBC as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey.
Yahoo
10-07-2025
- Business
- Yahoo
Mizuho Lowers PT on Embecta Corp. (EMBC) to $13 From $15, Keeps a Neutral Rating
Embecta Corp. (NASDAQ:EMBC) is one of the 13 Cheap Healthcare Stocks with Huge Upside Potential. On May 23, Mizuho lowered the firm's price target on Embecta Corp. (NASDAQ:EMBC) to $13 from $15, keeping a Neutral rating on the shares. The rating came after analyst day, with the firm telling investors in a research note that the company's long-term guidance calls for sales to stay relatively flat through 2028. An assembly line of medical devices being packed for distribution. Following similar circumstances, Travis Steed from Bank of America Securities maintained a Sell rating on Embecta Corp. (NASDAQ:EMBC) in a report released on May 28, setting a price target of $18.00. Embecta Corp. (NASDAQ:EMBC) provides medical devices used to treat diabetes. The company's offerings include syringes, pen needles, and safety devices fitted with a digital application. While we acknowledge the potential of EMBC as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
26-06-2025
- Business
- Yahoo
Embecta Corp. (EMBC) Lowered FY25 Guidance Amid Foreign Exchange Challenges
River Road Asset Management, an investment management company, released its 'River Road Small Cap Value Fund' Q1 2025 investor letter. A copy of the letter can be downloaded here. In the first quarter, AMG River Road Small Cap Value Fund (Class N) returned -3.94% compared to -7.74% returns for the Russell 2000 Value Index. The fund returned 1.30% for the one year ended March 31, 2025, compared to the index return of -3.12%. Stocks declined in the first quarter due to diminishing growth expectations and uncertainty surrounding trade policies, which crumbled the post-election increase in business, consumer, and investor confidence. The remaining gains were subsequently erased following 'Liberation Day.' For more information on the fund's best picks in 2025, please check its top five holdings. In its first-quarter 2025 investor letter, River Road Small Cap Value Fund highlighted stocks such as Embecta Corp. (NASDAQ:EMBC). Embecta Corp. (NASDAQ:EMBC) is a medical device company that focuses on the treatment of diabetes. The one-month return of Embecta Corp. (NASDAQ:EMBC) was -5.02%, and its shares lost 20.30% of their value over the last 52 weeks. On June 25, 2025, Embecta Corp. (NASDAQ:EMBC) stock closed at $9.93 per share, with a market capitalization of $580.334 million. River Road Small Cap Value Fund stated the following regarding Embecta Corp. (NASDAQ:EMBC) in its Q1 2025 investor letter: "The holding with the lowest contribution to active return in the portfolio during Q1 was Embecta Corp. (NASDAQ:EMBC), the world's #1 global provider of pen needles and syringes for insulin injections with more than eight billion units sold annually. EMBC reported better-than expected F1Q25 results but lowered FY25 revenue guidance due to foreign exchange headwinds following the recent appreciation of the U.S. Dollar." An assembly line of medical devices being packed for distribution. Embecta Corp. (NASDAQ:EMBC) is not on our list of 30 Most Popular Stocks Among Hedge Funds. As per our database, 29 hedge fund portfolios held Embecta Corp. (NASDAQ:EMBC) at the end of the first quarter, which was 21 in the previous quarter. In the fiscal second quarter of 2025, Embecta Corp. (NASDAQ:EMBC) generated $259 million in revenue, reflecting a 9.8% decline year-over-year on a reported basis. While we acknowledge the potential of Embecta Corp. (NASDAQ:EMBC) as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns, and doing so within a shorter timeframe. If you are looking for an AI stock that is as promising as NVIDIA but that trades at less than 5 times its earnings, check out our report about the undervalued AI stock set for massive gains. In addition, please check out our hedge fund investor letters Q1 2025 page for more investor letters from hedge funds and other leading investors. While we acknowledge the potential of PGNY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Globe and Mail
10-06-2025
- Business
- Globe and Mail
Pen Needles Market to Hit USD 3.08 Billion by 2030 with 9.2% CAGR
"Key players in this market are adopting several organic and inorganic growth strategies (such as product launches, agreements, collaborations, acquisitions, and expansions). Prominent players in this market include Embecta Corp. (US), Novo Nordisk A/S (Denmark), Ypsomed AG (Switzerland)" Browse 267 market data Tables and 71 Figures spread through 285 Pages and in-depth TOC on "Pen Needles Market by Type (Standard Pen Needles, Safety Pen Needles), Length (8mm, 5mm), Setting (Home Care Settings), Application (Glucagon-Like Peptide-1 Therapy), Mode of Purchase (Over the Counter Purchase, Online Purchase) - Global Forecast to 2030 The pen needles market valued at US$ 1.69 Billion in 2023, is forecasted to grow at a robust CAGR of 9.2%, reaching US$ 1.81 Billion in 2024 and an impressive US$ 3.08 Billion by 2030. The pen needles market has been segmented based on type, length, application, mode of purchase, setting and region. The key factors driving the market growth of the pen needles market include the rising incidence of chronic diseases, favourable reimbursements in certain countries, and decreasing prices of insulin formulations. Factors that provide opportunities for market players include the growing preference for biosimilar drugs, emerging economies to offer high-growth potential, and rising healthcare expenditure on diabetes. Supportive government regulations, such as rigorous safety standards by the US FDA and favourable reimbursement policies, are also expected to fuel the uptake of technologically advanced products. A combination of these factors is expected to facilitate the increased adoption of pen needles in healthcare systems. Browse in-depth TOC on ' Pen Needles Market' 200 - Tables 80 - Figures 300 - Pages In this report, the pen needles market has been segmented on the basis of type, length, application, mode of purchase, setting and region. The pen needles market is segmented into standard pen needles and safety pen needles on the basis of type. Standard pen needles are budget-friendly needles for insulin delivery, which explains their popularity in low-income markets and among the uninsured. These needles are simple and basic, which makes them easier to manufacture. There is no requirement for ultra-thin design or sophisticated coating that is required for more expensive options. Cost is a major determinant in healthcare in developing nations and low-income brackets. With standard pen needles, accessible options for diabetic patients who need insulin therapy are readily available without worry of financial suffocation. Moreover, for the Grey market practioners in developed countries where people do not have insurance, these needles are a cheap and functional alternative. Thus, standard pen needles are vital because they meet minimum requirements of diabetes control which helps increase the availability of insulin delivery worldwide. The pen needles market is segmented into prescription-based, over the counter (OTC) purchase, online purchase and other modes of purchase on the basis of mode of purchase. Online purchase segment is expected to grow at the highest CAGR during the forecast period of the global pen needles market. As e-commerce grows across the world, the demand for pen needles is also on the rise as new customers are drawn to online shopping. Marketplaces make purchase easier for patients who can now shop for pen needles among other products while sitting in their homes. This is particularly helpful for people with movement disabilities or people living in far flung areas who don't have a ready access to local pharmacies. Businesses engaged in diabetes care and treatment are benefiting enormously as most e-commerce websites offer better rates, promotions, and subscriptions which aid in controlling diabetes. Furthermore, aspects like covert packaging and home delivery make e-commerce users feel more secure and comfortable. The vast variety of products and brands available in these platforms allows customers more purchasing freedom, which aids in increasing their adoption. The pen needles market is segmented into North America, Europe, Asia Pacific, Latin America, Middle East, and Africa and GCC Countries on the basis of geographic region. North America holds the largest share of the pen needles market in 2024. North America sees one of the maximum diabetes prevalence rates of the world with the U.S and Canada heads in the top of the insulin-dependent population. As per CDC, more than 37 million Americans suffer from diabetes, and approximately 1.6 million have type 1 diabetes. Thus, Canada also bears a huge burden of diabetes cases with an estimated total of 11.7 million that are affected by diabetes or prediabetes. The prevalence of such patients is relatively high, thus increasing demand for pen needles since it's the basic need for managing blood glucose. Pen needles require good infrastructure and wide awareness in place with patients desiring easy-to-handle devices such as pen needles, thereby augmenting the uptake of this equipment. Increased concern regarding proper management of diabetes helps in sustaining the demand in the region. Prominent players in this market include Embecta Corp. (US), Novo Nordisk A/S (Denmark), Ypsomed AG (Switzerland), B. Braun SE (Germany), Owen Mumford (UK), Terumo Corporation (Japan), NIPRO Corporation (Japan), Allison Medical, Inc. (US), AdvaCare Pharma (US), Berpu Medical Technology Co., Ltd. (China), ARKRAY, Inc. (Japan), GlucoRx Limited (UK), HTL-STREFA (Poland), UltiMed, Inc. (US), Hindustan Syringes and Medical Devices (India), Artsana Group (Italy), PromiseMed Medical Devices Inc. (Canada), Montmed, Inc. (Canada), Trividia Health, Inc. (US), VOGT Medical Vertrieb GmbH (Germany), Van Heek Medical (Netherlands), Simple Diagnostics (US), IYON Medical (Turkey), Links Medical Products, Inc. (US), and MHC Medical Products, LLC (US). EMBECTA CORP. (US) One of the main products traded by Embecta in the global market is pen needles. The company operates from a US-based facility, as well as having production plants in Ireland and China. The company's vast range of pen needles, syringes, and safety injection devices is a fundamental factor that helps it withstand competition in global market. Alongside the standard pen needles, the company has a safety pen needle portfolio. The company approaches the growth by both inorganic and organic mechanisms to cement its position in the pen needle market. For instance, on November 2022, Embecta Corporation (US) signed a agreement with Intuity Medical, Inc. (US) under which Embecta sales representatives in the US will promote Intuity Medical's high-tech POGO automatic blood glucose monitoring system to healthcare professionals. NOVO NORDISK A/S (DENMARK) The major source of revenue for the company is its Diabetes and Obesity Care segment. The global diabetes market provides an opportunity for the firm to generate revenues through its Diabetes Care segment. The company obtained approximately 40 million diabetic patients in 2022, from 32 million in Nordisk is well poised in production with ~16 production sites across five regions and a growing product portfolio, including pen needles. The R&D centers of the company are set up in China, Denmark, India, the UK, and the US. Novo Nordisk increased R&D investments from 13.6% in 2022 to 14.0% in 2023. The company also announced that it would be expanding its presence in the pen needles market through a research hub in the greater Boston metro area, which was announced in March 2023. B. BRAUN SE (GERMANY) B. Braun SE is another major player of the pen needle market. In terms of product, the group has a comprehensive presence across geographical boundaries. Also, it has recognition for its branded products, notably Omnican Fine and Omnican Fine Plus injection pen needles. The innovations included in the products such as three facet grinding tip and silicone coating or thin-wall technologies used for injecting pen needles will help the firm obtain a strong presence in branding at the overall markets. The company has a huge geographical presence and subsidiaries in 64 countries. Therefore, it is not dependent on a single market, thus sustaining its leading position. The company intends to focus on new technology and digital transformation for healthcare medical devices. For more information, Inquire Now!
